US.VTRS · Viatris

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.258233302554632,
        "turnoverUsdM": 91.43183097,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.VTRS",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 15.1864,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 1,
        "rsi_score": 2.5,
        "macd_score": 1,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.5,
      "take_profit_price": 17.0919,
      "target_multiplier": 1.6,
      "technical_strength": 1.5,
      "take_profit_percent": 5.2
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.516466605109264,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 57,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 52,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 16.9218,
    "ma50": 16.5945,
    "close": 16.25,
    "prevClose": 16.17,
    "avgVolume20": 10781645,
    "volumeRatio": 0.52,
    "changePercent": 0.46
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": 0.009006211180124124,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 0.5011163656615057,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.7331967988072298,
      "volat_points": 0,
      "day_range_pct": 0.021545090797168227,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 57,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 44,
        "contribution": 2.2
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 8.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 57.33,
        "contribution": 8.6
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 63,
        "contribution": 6.3
      },
      {
        "raw": 12.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 41.67,
        "contribution": 12.5
      },
      {
        "raw": 8,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 80,
        "contribution": 8
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 52,
    "details": [
      "基本面分析總分: 2.2/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 8.6/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.3/10分",
      "技術信號分析總分: 12.5/30分",
      "情緒分析: 8/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 2.2,
      "資金流": 8.4,
      "市場環境": 8.6,
      "情緒分析": 8,
      "技術信號": 12.5,
      "風險管理": 6.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 91.43183097,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VTRS",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.84
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 706.7795018500002,
                "ma50": 712.9846024399999,
                "name": "QQQ",
                "close": 716.080017,
                "points": 1.4
              },
              "spy": {
                "ma20": 759.7665036499999,
                "ma50": 750.4328049600001,
                "name": "SPY",
                "close": 769.059998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.258233302554632,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "優秀",
        "items": {
          "sentiment": {
            "score": 8,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 6,
              "sentimentScoreRaw": 1.8
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141212270,
                "url": "https://finnhub.io/api/news?id=015a862c9cfefa43e5a4ba9b1dd7ee8d21d7e76650cfba1ac69b61c7cf20e618",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]",
                "category": "company",
                "datetime": 1786662197,
                "headline": "Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?"
              },
              {
                "id": 141209618,
                "url": "https://finnhub.io/api/news?id=15b80dcfe1d6812445478ace4f44b8aff1a1ffba400a6554bd0bdd030d93ed0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Greater China surges 16% as management raises full-year guidance.",
                "category": "company",
                "datetime": 1786644802,
                "headline": "Viatris (VTRS) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141183723,
                "url": "https://finnhub.io/api/news?id=ecc5329b5d0acd7547eeabf49fd4aa24eef91a549cd10d9ecb33bc11972062cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1786438402,
                "headline": "VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook"
              },
              {
                "id": 141170778,
                "url": "https://finnhub.io/api/news?id=d3f01bc0450eb5e03b3ea7ad21d6d6bc9fc00521f25654167dd32877826e10a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. An interesting angle is that Viatris paired improved earnings and guidance with both capital returns and the FDA approval of its low-estrogen Gwyn Lo contraceptive patch,...",
                "category": "company",
                "datetime": 1786324461,
                "headline": "Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program"
              },
              {
                "id": 141169348,
                "url": "https://finnhub.io/api/news?id=c479966aceb7b59725b6780cebcc3c5e39e37d2b5dbf6db60dc52e6b9a30bdac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be pricing in less than the company’s fundamentals could justify. Viatris is up 76.1% over the last 12 months, which puts more focus on whether the recent share price better reflects the company’s long term earnings power. Recent product news, including the FDA approval of the Gwyn Lo contraceptive patch and the agreement to transfer rights to TYRVAYA nasal...",
                "category": "company",
                "datetime": 1786306239,
                "headline": "Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval"
              },
              {
                "id": 141167083,
                "url": "https://finnhub.io/api/news?id=d47b3ea75236beefba1a9dbe9725d95eb69b4bfba303b43cdeef86522839f19c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris raises 2026 guidance alongside completed buyback and fresh product approval Viatris (VTRS) has given investors a busy early August, pairing raised 2026 revenue guidance and completion of a multi year share repurchase program with new product news and an affirmed quarterly dividend. See our latest analysis for Viatris. The recent guidance lift, completion of a US$1.15b buyback and fresh product approval come after a strong run for Viatris, with a year to date share price return of...",
                "category": "company",
                "datetime": 1786284618,
                "headline": "Viatris (VTRS) Raises 2026 Guidance, Is The 11% Gap Below Fair Value Enough?"
              },
              {
                "id": 141165625,
                "url": "https://finnhub.io/api/news?id=9fc76c096fd1ea466602cbaf3a51f371145d6964e4b63c0088a5df66f7ed1712",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The latest research on Viatris centers on a revised price target of US$22 per share and what that figure implies for investors following the story. Analysts are split, with more optimistic views pointing to execution on the product pipeline and cautious views questioning how fully the current stock price already reflects those expectations. As the article continues, you will see how this updated target fits into the evolving narrative around Viatris and how you can track the key signposts...",
                "category": "company",
                "datetime": 1786266704,
                "headline": "Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress"
              },
              {
                "id": 141142427,
                "url": "https://finnhub.io/api/news?id=860dd4c56ada7b117ed8cbc6ba386dcb0c9515532493744882b82679c6b91ccb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc (VTRS) delivers 3.5% operational revenue growth and raises full-year 2026 guidance, while navigating supply disruptions and competitive pressures.",
                "category": "company",
                "datetime": 1786058074,
                "headline": "Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ..."
              }
            ],
            "raw_source": [
              {
                "id": 141212270,
                "url": "https://finnhub.io/api/news?id=015a862c9cfefa43e5a4ba9b1dd7ee8d21d7e76650cfba1ac69b61c7cf20e618",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]",
                "category": "company",
                "datetime": 1786662197,
                "headline": "Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?"
              },
              {
                "id": 141209618,
                "url": "https://finnhub.io/api/news?id=15b80dcfe1d6812445478ace4f44b8aff1a1ffba400a6554bd0bdd030d93ed0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Greater China surges 16% as management raises full-year guidance.",
                "category": "company",
                "datetime": 1786644802,
                "headline": "Viatris (VTRS) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141197531,
                "url": "https://finnhub.io/api/news?id=0ad00594b320b2b62379bd020b3f4d60a6b2410c1cb6d0ad82ea849220b24214",
                "image": "",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "",
                "category": "company",
                "datetime": 1786564051,
                "headline": "Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio: Q2 2026 Update"
              },
              {
                "id": 141204249,
                "url": "https://finnhub.io/api/news?id=514a0a0b9166eae70ba0c9749ac7216a60523a1519e88ba7e93b0d972bb57225",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.",
                "category": "company",
                "datetime": 1786549860,
                "headline": "Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?"
              },
              {
                "id": 141202568,
                "url": "https://finnhub.io/api/news?id=fb6686ad236ea7926fe44ec7cd957de69e689e45471e0d3b74ef6f5557886ba8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.",
                "category": "company",
                "datetime": 1786455000,
                "headline": "TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks"
              },
              {
                "id": 141183723,
                "url": "https://finnhub.io/api/news?id=ecc5329b5d0acd7547eeabf49fd4aa24eef91a549cd10d9ecb33bc11972062cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1786438402,
                "headline": "VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook"
              },
              {
                "id": 141170778,
                "url": "https://finnhub.io/api/news?id=d3f01bc0450eb5e03b3ea7ad21d6d6bc9fc00521f25654167dd32877826e10a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. An interesting angle is that Viatris paired improved earnings and guidance with both capital returns and the FDA approval of its low-estrogen Gwyn Lo contraceptive patch,...",
                "category": "company",
                "datetime": 1786324461,
                "headline": "Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program"
              },
              {
                "id": 141169348,
                "url": "https://finnhub.io/api/news?id=c479966aceb7b59725b6780cebcc3c5e39e37d2b5dbf6db60dc52e6b9a30bdac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be pricing in less than the company’s fundamentals could justify. Viatris is up 76.1% over the last 12 months, which puts more focus on whether the recent share price better reflects the company’s long term earnings power. Recent product news, including the FDA approval of the Gwyn Lo contraceptive patch and the agreement to transfer rights to TYRVAYA nasal...",
                "category": "company",
                "datetime": 1786306239,
                "headline": "Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval"
              },
              {
                "id": 141167083,
                "url": "https://finnhub.io/api/news?id=d47b3ea75236beefba1a9dbe9725d95eb69b4bfba303b43cdeef86522839f19c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris raises 2026 guidance alongside completed buyback and fresh product approval Viatris (VTRS) has given investors a busy early August, pairing raised 2026 revenue guidance and completion of a multi year share repurchase program with new product news and an affirmed quarterly dividend. See our latest analysis for Viatris. The recent guidance lift, completion of a US$1.15b buyback and fresh product approval come after a strong run for Viatris, with a year to date share price return of...",
                "category": "company",
                "datetime": 1786284618,
                "headline": "Viatris (VTRS) Raises 2026 Guidance, Is The 11% Gap Below Fair Value Enough?"
              },
              {
                "id": 141165625,
                "url": "https://finnhub.io/api/news?id=9fc76c096fd1ea466602cbaf3a51f371145d6964e4b63c0088a5df66f7ed1712",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The latest research on Viatris centers on a revised price target of US$22 per share and what that figure implies for investors following the story. Analysts are split, with more optimistic views pointing to execution on the product pipeline and cautious views questioning how fully the current stock price already reflects those expectations. As the article continues, you will see how this updated target fits into the evolving narrative around Viatris and how you can track the key signposts...",
                "category": "company",
                "datetime": 1786266704,
                "headline": "Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress"
              },
              {
                "id": 141142427,
                "url": "https://finnhub.io/api/news?id=860dd4c56ada7b117ed8cbc6ba386dcb0c9515532493744882b82679c6b91ccb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc (VTRS) delivers 3.5% operational revenue growth and raises full-year 2026 guidance, while navigating supply disruptions and competitive pressures.",
                "category": "company",
                "datetime": 1786058074,
                "headline": "Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ..."
              },
              {
                "id": 141142220,
                "url": "https://finnhub.io/api/news?id=19958454e495e0677320ccc5ffb93f2bb0317ad45867b96d325a99f919434def",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Viatris Inc. (VTRS) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDTCompany ParticipantsWilliam Szablewski - Head of Investor Relations & Capital...",
                "category": "company",
                "datetime": 1786045460,
                "headline": "Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141137503,
                "url": "https://finnhub.io/api/news?id=e4556501b54dbd5e8d2f4d3611ccfcd7d71daa3264046de226b93fa1b087274c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.",
                "category": "company",
                "datetime": 1786030860,
                "headline": "VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump"
              },
              {
                "id": 141147475,
                "url": "https://finnhub.io/api/news?id=8f48f208d16e38950fc479065ed145a3f754e48a80ee9278c8306f358d07a1fa",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Health-care-And-Medicine.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.",
                "category": "company",
                "datetime": 1786024600,
                "headline": "Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook"
              },
              {
                "id": 141136772,
                "url": "https://finnhub.io/api/news?id=b1e63cfddae95aa38f1c36d04f5e524a1cdfcf5956bad269bc6d704beca55c0f",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "2026-08-06. The following slide deck was published by Viatris Inc.",
                "category": "company",
                "datetime": 1786023079,
                "headline": "Viatris Inc. 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141135731,
                "url": "https://finnhub.io/api/news?id=a2315aaa677a3af8abdbe820762187b734f91638a27a3c59e03f7174b6c039fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1786023007,
                "headline": "Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics"
              },
              {
                "id": 141134293,
                "url": "https://finnhub.io/api/news?id=86d7b5db8cf41ec5dec01bb43344afd37946fa9621915bcb20489b8968258b7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris (VTRS) delivered earnings and revenue surprises of +11.29% and +2.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1786018812,
                "headline": "Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates"
              },
              {
                "id": 141133390,
                "url": "https://finnhub.io/api/news?id=2834f56a3b08e736761d086e1b2153a7fac7aef17aec88995153502c12f677a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year’s revenue to be around $14.75 billion, close to analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1786016572,
                "headline": "Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026"
              },
              {
                "id": 141133391,
                "url": "https://finnhub.io/api/news?id=ae8116a92013013591ae1c21bc37edd6c8e6250b50350832bd784a3ecf39eff5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan,",
                "category": "company",
                "datetime": 1786014000,
                "headline": "Harrow Acquires Global Rights to TYRVAYA®,  the First and Only FDA-Approved Nasal Spray for Dry Eye Disease"
              },
              {
                "id": 141133392,
                "url": "https://finnhub.io/api/news?id=4788c9be58b4b65e624d51c99ba891cc36a5adbe7b0b5cf5288ff39a3a000eac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its second-quarter 2026 financial results.",
                "category": "company",
                "datetime": 1786013940,
                "headline": "Viatris Reports Second-Quarter 2026 Financial Results"
              },
              {
                "id": 141134528,
                "url": "https://finnhub.io/api/news?id=f95c5aadfd9cbcd795bcfa0e45689f621cbbd4a8b2bc125401c588176d912f24",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.60 by 15 percent. This is a 11.29 percent increase over earnings of $0.62 per share from the same",
                "category": "company",
                "datetime": 1786000033,
                "headline": "Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B Estimate"
              },
              {
                "id": 141134529,
                "url": "https://finnhub.io/api/news?id=86d517e59f34eca3b531b5a72a6930c1d45d5063526ae55b8c22b1e290a35115",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Viatris (NASDAQ:VTRS) raises FY2026 Adj EPS guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 analyst estimate. Raises FY2026 sales outlook from $14.450 billion-$14.950 billion to $14.550 billion-$14.950 billion vs",
                "category": "company",
                "datetime": 1785999615,
                "headline": "Viatris Raises FY2026 Adj EPS Guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 Est; Raises FY2026 Sales Guidance from $14.450B-$14.950B to $14.550B-$14.950B vs $14.783B Est"
              },
              {
                "id": 141126014,
                "url": "https://finnhub.io/api/news?id=4ca154ba64515bee5ba02348b2bcfc96c4b3f716d2aaef53bf1dd2abbbbb6145",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217256698/image_2217256698.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Teva Pharmaceutical Industries Limited turnaround: Pivot to Growth, raised 2026 guidance, $3.7B specialty target, and more. Click for this TEVA update.",
                "category": "company",
                "datetime": 1785945929,
                "headline": "Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan"
              },
              {
                "id": 141122780,
                "url": "https://finnhub.io/api/news?id=56a37080ea5be3e4342ba285b15bfbb3c784c17a40c421631e0dbcf7afcfb51d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Beyond analysts' top-and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.",
                "category": "company",
                "datetime": 1785935706,
                "headline": "Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures"
              },
              {
                "id": 141121326,
                "url": "https://finnhub.io/api/news?id=cbf9a1407c933e2d5b65007acd102a76795412d5fbdb041da0e43e30c5221014",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "CVS Health (CVS) delivered earnings and revenue surprises of +37.97% and +5.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785930303,
                "headline": "CVS Health (CVS) Q2 Earnings and Revenues Beat Estimates"
              },
              {
                "id": 141112039,
                "url": "https://finnhub.io/api/news?id=86dfde268f125ac90cf66ad9a83ef883460cbdaa179a69d077910a3b528fcdfa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.",
                "category": "company",
                "datetime": 1785857820,
                "headline": "Viatris Gears Up to Report Q2 Earnings: What's in the Cards?"
              },
              {
                "id": 141115186,
                "url": "https://finnhub.io/api/news?id=df441055c1b1ceff040a1e8e49d1e21b8c76676bd1039d0f0937736d2adb1c9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Though Viatris has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.",
                "category": "company",
                "datetime": 1785855253,
                "headline": "Is Wall Street Bullish or Bearish on Viatris Stock?"
              },
              {
                "id": 141107906,
                "url": "https://finnhub.io/api/news?id=c17cd804f71427173123320060d4d7ebf7d68aa13ac16cbc80259d64dca660fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS) today announced that on August 3, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 16, 2026, to shareholders of record as of the close of business on August 21, 2026.",
                "category": "company",
                "datetime": 1785841140,
                "headline": "Viatris Announces Quarterly Dividend"
              },
              {
                "id": 141104328,
                "url": "https://finnhub.io/api/news?id=9f2befff5435b6c845aef8b61bf7e63277adb78b6bf53c874142248016e63b5d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of +105.26% and +4.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785793506,
                "headline": "GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Surpass Estimates"
              },
              {
                "id": 141101634,
                "url": "https://finnhub.io/api/news?id=3b8d7685faae47c2e62084900c928db6ed484e9b6ae9337040d701e1897089e1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2179947933/image_2179947933.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Viatris looks fairly valued after a 95% rally. Click for more on VRTS stock.",
                "category": "company",
                "datetime": 1785766795,
                "headline": "Viatris: A Reasonable Valuation"
              },
              {
                "id": 141094362,
                "url": "https://finnhub.io/api/news?id=b35acf1a7ff78815105a66df920a37b8a3967ab6f0c0c1d4361d43c546a92ab6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris received U.S. FDA approval for its new combined hormonal contraceptive patch, Gwyn Lo. The product is a low dose estrogen contraceptive patch with data supporting efficacy and safety. This approval adds a fresh option to Viatris' women’s health portfolio and may influence its U.S. market position. For investors watching Viatris (NasdaqGS:VTRS), the Gwyn Lo approval comes at a time when the stock has shown strong momentum. The current share price of $17.56 comes alongside a 40.9%...",
                "category": "company",
                "datetime": 1785690822,
                "headline": "Viatris (VTRS) Wins FDA Approval For Gwyn Lo Contraceptive Patch"
              },
              {
                "id": 141082293,
                "url": "https://finnhub.io/api/news?id=47bdb4f92c4fcd1ac1e342ca45dd31e6bd1624882562a0dd56dddf3ee970f21b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1391441819/image_1391441819.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Viatris is rated a Sell due to persistent risks, weak financials, and a likely profit-taking event post-Q2 2026 earnings. Read more on VTRS stock here.",
                "category": "company",
                "datetime": 1785518138,
                "headline": "Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run"
              },
              {
                "id": 141066826,
                "url": "https://finnhub.io/api/news?id=971c787ccfe80e044086989bf55b5f290d451c2c99c0681c7a97d62a0135e510",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785420007,
                "headline": "Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?"
              },
              {
                "id": 141052274,
                "url": "https://finnhub.io/api/news?id=629a16f9a110ca6390915ef33dcc6edb2e0cb4ad8a1fc010a1d41932608ac95d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo is a new combined hormonal contraceptive (CHC) patch with low-dose estrogen. The patch has demonstrated contraceptive efficacy for women of childbearing potential with a body mass index (BMI) below 30 kg/m² who are appropriate candidates for CHC. The Gwyn Lo dosage is norelgestromin 220",
                "category": "company",
                "datetime": 1785322740,
                "headline": "Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch"
              },
              {
                "id": 141051465,
                "url": "https://finnhub.io/api/news?id=e647d1716ec00a85f9d2c23ab796255fbeae0bc83ad0134ed09ba88d96efd30a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/910130768/image_910130768.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "I analyze 90 top Ten-Year Collected Dividend Dogs (a.k.a. “Decadean”), focusing on yield-based selection and safety via free cash flow coverage.",
                "category": "company",
                "datetime": 1785303575,
                "headline": "18 Ideal 'Safer' Buyable July Dogs Emerge After 10 Years Of Digging"
              },
              {
                "id": 141049160,
                "url": "https://finnhub.io/api/news?id=91ac7482f56b0cd6df5e0f96b4da4dd0228d7597eedd004d39e10547024499a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with Viatris (NASDAQ:VTRS).",
                "category": "company",
                "datetime": 1785289262,
                "headline": "Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)"
              },
              {
                "id": 141007905,
                "url": "https://finnhub.io/api/news?id=0937114de2f22440918b6a30cab795b1b3815aa085c5bcd0f0d07936b7f3ff4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.7% gain over the past six months, beating the S&P 500 by 1.8 percentage points.",
                "category": "company",
                "datetime": 1784910788,
                "headline": "3 Healthcare Stocks We Keep Off Our Radar"
              },
              {
                "id": 141011052,
                "url": "https://finnhub.io/api/news?id=49acf6924845a32bcf0ca6f68a718ce2268884991fb74f4c2348fd4dc9cfc903",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "https://www.ema.europa.eu/en/medicines/human/EPAR/ruxolitinib-viatris",
                "category": "company",
                "datetime": 1784874941,
                "headline": "Viatris Receives EMA CHMP Recommendation For Approval Of Ruxolitinib Viatris For The Treatment Of Myelofibrosis, Polycythaemia Vera And Graft-Vs-Host Disease"
              },
              {
                "id": 140986463,
                "url": "https://finnhub.io/api/news?id=0d5933a5447b91a63d41518b04062f1294db1e80886142b089acd061ad28d640",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Generic drugmakers face U.S. manufacturing deadlines as India and global suppliers weigh potential tariff impact.",
                "category": "company",
                "datetime": 1784750205,
                "headline": "Trump Proposes 200% Generic Drug Tariffs, Sandoz Shares Drop 4.2%"
              },
              {
                "id": 140984983,
                "url": "https://finnhub.io/api/news?id=7a984fbdc861fe25fe1a43cc59c8e77d35b46db2287536fae3fe4afbffb73899",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris is scheduled to report its second-quarter results next month, with Wall Street expecting earnings per share to remain roughly unchanged from a year ago.",
                "category": "company",
                "datetime": 1784717109,
                "headline": "Viatris’ Quarterly Earnings Preview: What You Need to Know"
              },
              {
                "id": 140984401,
                "url": "https://finnhub.io/api/news?id=4369f6334decadfe5ab77ef01f15b89812491b70469ba6424682360f7177141b",
                "image": "https://image.cnbcfm.com/api/v1/image/108336351-1784251467141-gettyimages-2285785852-AFP_C2EX37T.jpeg?v=1784251495&w=1920&h=1080",
                "source": "CNBC",
                "related": "VTRS",
                "summary": "Trump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear.",
                "category": "company",
                "datetime": 1784711665,
                "headline": "Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply"
              },
              {
                "id": 140958808,
                "url": "https://finnhub.io/api/news?id=a9f38dfe57dce34baf1fb301ab529faf7cde997e4fdf9d8c53b1bdae9cfa39a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1784546853,
                "headline": "3 Unpopular Stocks We’re Skeptical Of"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 6,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.8,
            "source_article_count": 42,
            "discarded_article_count": 25
          },
          "sentimentPoints": 8
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 12.5,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0,
            "vcp_reason": "Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 2,
              "vol_ref": 10299370,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 12627820,
              "avg_vol_20": 11231535,
              "avg_vol_30": 10299370,
              "range_pct_10": 0.15450907971683592,
              "range_pct_20": 0.15450907971683592,
              "range_pct_30": 0.15450907971683592,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.2260769348028084,
              "dist_to_20d_high": 0.11663947797716147,
              "down_shrink_days": 1,
              "breakout_level_20d": 18.39,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 1
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.258233302554632,
              "turnoverUsdM": 91.43183097,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.VTRS",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 15.1864,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 1,
              "rsi_score": 2.5,
              "macd_score": 1,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.5,
            "take_profit_price": 17.0919,
            "target_multiplier": 1.6,
            "technical_strength": 1.5,
            "take_profit_percent": 5.2
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.516466605109264,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 0.5293,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.26
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -65.17
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1491
    },
    "kdj": {
      "d": 17.12,
      "j": 30.33,
      "k": 21.53,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 31.84
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -48251294,
      "recentSlope": -2519129.4,
      "previousSlope": -3408420
    },
    "rsi": 20.92,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 16.848,
      "position": "SAR喺價上",
      "distancePct": 3.71,
      "previousTrend": "下降"
    },
    "ma50": 16.5945,
    "macd": {
      "macd": -0.19486854936349118,
      "trend": "看跌",
      "signal": -0.0710092236510032,
      "histogram": -0.12385932571248798
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 16.9165,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.52,
      "score": 2,
      "avgVolume": 10781645,
      "currentVolume": 5628306
    },
    "derived": {
      "ma20": 16.9218,
      "ma50": 16.5945,
      "prevClose": 16.17,
      "avgVolume10": 12055571,
      "avgVolume20": 10781645,
      "changePercent": 0.46,
      "avgVolumeForScore": 10781645
    },
    "ma_cross": {
      "ma20": 16.9218,
      "ma50": 16.5945,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 16.96,
      "prevMa50": 16.5882,
      "spreadPct": 1.97,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 15.502,
      "upper": 18.3415,
      "position": "中間"
    },
    "rsi_short": 46.9,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.52
    }
  }
}

{
  "close": 16.25,
  "volume": 5628306,
  "changePercent": 0.46
}